GBT - Global Blood Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.75
-0.01 (-0.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close46.76
Open46.77
Bid0.00 x 800
Ask67.30 x 800
Day's Range46.45 - 48.12
52 Week Range30.15 - 68.05
Volume549,525
Avg. Volume1,306,409
Market Cap2.596B
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-3.40
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est87.00
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on January 1, 2019, the compensation.

  • GlobeNewswire15 days ago

    GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37th Annual J.P. Morgan Healthcare.

  • GlobeNewswire27 days ago

    GBT Appoints Dawn Svoronos to Board of Directors

    Global Blood Therapeutics, Inc. (GBT) (GBT) today announced the appointment of Dawn Svoronos to the company’s board of directors. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia, including a nearly 25-year tenure at Merck & Co. “Dawn is a global biopharmaceutical leader whose addition to the board will strengthen the existing breadth of talent,” said Ted W. Love, M.D., president and chief executive officer of GBT.

  • Ghost Tree Capital’s AUM, Returns and Holdings
    Insider Monkeylast month

    Ghost Tree Capital’s AUM, Returns and Holdings

    David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]

  • Here's Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since
    Motley Foollast month

    Here's Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since

    The company reported boring third-quarter 2018 operating results, but followed up with important clinical updates in the first week of December.

  • ACCESSWIRElast month

    Global Blood Therapeutics, Voxelotor in Advanced Clinicals, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Global Blood Therapeutics , Inc. (GBT), a clinical-stage biopharmaceutical company. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. GBT plans to request a pre-NDA meeting for the first quarter of 2019 and intends to provide further details regarding its plans and timing for an NDA submission as well as additional specifics on the TCD confirmatory study following this meeting.

  • GlobeNewswirelast month

    Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering

    Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT. In addition, GBT has granted the underwriters a 30-day option to purchase $22.5 million of additional shares of common stock. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.

  • Benzingalast month

    The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...

  • 3 Biotech Stocks That Could Explode Higher in 2019
    SmarterAnalystlast month

    3 Biotech Stocks That Could Explode Higher in 2019

    Black Friday is past. So is Cyber Monday. But it's not too late to buy one of the best Christmas gifts of all -- biotech stocks. Analysts think there are three biotech stocks, in particular, that look like good picks right now: Stemline Therapeutics (STML), Global Blood Therapeutics (GBT), and Sesen Bio (SESN). Let's take a closer look. Stemline: Analysts See 200% Gains Ahead of Upcoming FDA Decision Stemline filed a biologics license application (BLA) for its lead drug candidate, ELZONRIS (SL-401), which in October 2017 reported promising phase 2 data as a first-line treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN). The application has received priority review from the FDA and has a PDUFA date scheduled for February 21, 2019, which is when regulators will decide the drug's commercial fate. ELZONRIS has also been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA. "Given the strength of the pivotal study data combined with the significant unmet clinical need for BPDCN patients, we believe there is a strong likelihood of approval by the PDUFA date," Ladenburg analyst Matthew Kaplan opined. "We believe SL-401 could generate >$130 million U.S. revenues in the BPDCN indication at peak. We are encouraged by the progress of STML’s commercial preparations and look forward to updates as we move closer to the PDUFA date." Kaplan rates STML shares a Buy with a price target of $41, which implies a potential upside of nearly 300% from current levels. Wedbush's top analyst David Nierengarten added, "With stock trading near the lower end of its YTD range we would recommend investors accumulate shares going into what is likely to be a straightforward approval process for SL-401. With Breakthrough Status and BLA submitted we believe -401 is poised to be approved in early 2019, and we have confidence that STML can make a successful transition into a commercial company given small size of BPDCN market. With an EV of just about $400M, which is also what we approximate peak SL-401 sales at, we see STML as an attractive and easily digestible takeover target." (To watch Nierengarten's track record, click here) Bottom line: When it comes to Wall Street’s bet, the odds are on this biotech stock, with TipRanks analytics showcasing STML as a Strong Buy. With an average price target of $30.80, analysts are predicting massive upside potential of about 200% for the stock. In total, Stemline stock has received 6 'buy' ratings in the last three months. Global Blood: Clear Shot at Accelerated Approval Monday, Global Blood provided positive regulatory update on potential accelerated approval for Voxelotor in sickle cell disease (SCD) after consulting with the FDA. The company plans to have a pre-NDA FDA meeting in Q1:19 and possibly start submitting regulatory filings with a NDA in H2 2019. In reaction, Wedbush analyst Liana Moussatos boosted her price target on GBT stock to $93 (from $73), while reiterating an Outperform rating. Moussatos commented, "We remain comfortable with our August 2020 U.S. launch timing, $40.1 million 2020 sales estimate and achieving more than $1 billion in 2023. Although GBT stock greatly appreciated on December 3rd with this news, it should not be a surprise after positive comments from key opinion leaders (KOLs) participating in the FDA-ASH SCD Clinical Endpoints Workshop (October 17-18, 2018; Rockville, MD) were supportive of elevated hemoglobin in SCD (to treat hemolysis) as a primary endpoint for accelerated approval. Due to anticipated reduced regulatory and clinical risk and positive expanded HOPE Part A and HOPE-KIDS 1 results presented at ASH, we are increasing our multiple to 7x for positive Phase 3 results and raising our PT to $93 from $73. With GBT closing at $46.62 on December 3 after the news was released, we consider the stock to be undervalued in front of potentially major regulatory catalysts in 2019-2020. The Company ended Q3 with about $482.1 million in cash and we project runway into 2021 or longer depending on potential sales." Moussatos is not the only fan of the biotech company on Wall Street, as TipRanks analytics exhibit GBT as a Strong Buy. Based on 11 analysts polled in the last 3 months, 10 rate a Buy rating on Global Blood stock while only 1 recommends Hold. The 12-month average price target stands at $90.78, marking a 95% upside from where the stock is currently trading. Sesen: All Eyes on 6-Month Data Readout from VISTA Sesen is on-track to report updated six-month results from the ongoing Phase 3 VISTA study of Vicinium for the treatment of NMIBC in December. Recall, VISTA is a 134-patient, single-arm study with co-primary endpoints of complete response rate at 12 months and duration of response (DOR), and secondary endpoints of event-free survival, progression-free survival, overall survival, and time to cystectomy. The company previously published the initial 3-month readout back in May (39% CR rate), which was robust and within expectations. H.C. Wainwright's Swayampakula Ramakanth has weighed in with his two cents: "Based on the dinner discussions [with KOL], we believe that depending on the final VISTA results, Vicinium could have a compelling case for FDA approval. The more important factors in Vicinium’s favor are the current high unmet need for BCGunresponsive NMIBC and the drug’s excellent safety profile; with virtually no bladder-saving therapies available, a safe, proven treatment like Vicinium could enjoy a first-mover advantage with both the agency and with clinicians. In our view, Vicinium would very likely be approved should the drug achieve a 12-month complete response rate of >20% in VISTA, and should not be ruled out either if it only manages to repeat the previous 16% response rate achieved in Phase 2. Therefore, with regards to the upcoming six-month results, we believe that a response rate of >30% would be a strong positive for Sesen, while a rate on par with the 27% achieved in Phase 2 would still be on track for positive 12-month results." Ramakanth rates SESN stock a Buy with 12-month price target of $3.00, which implies a potential upside of nearly 87% upside from current levels. We can see from TipRanks that SESN has received 4 'buy ratings' in the past 12 months. Based on these ratings, the average $5.00 price target on the stock translates into upside of over 200% from the current share price. (See SESN's price targets and analyst ratings on TipRanks) #### More recent articles about GBT: * Sesen (SESN) Stock Just Lost a Bull * Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst * Global Blood Therapeutics (GBT) Gets Attention of FDA As Well As Investors * What Makes This Analyst Bullish About Bladder Cancer Treatment? Sesen Biopharma (SESN) Stock Could Be On the Rise

  • GlobeNewswirelast month

    Global Blood Therapeutics Announces Proposed Public Offering of Common Stock

    Global Blood Therapeutics, Inc. (GBT) (GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell $150.0 million in shares of its common stock in a registered underwritten public offering.  In addition, GBT has granted the underwriter a 30-day option to purchase up to $22.5 million in shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. GBT intends to use the net proceeds from the offering and its existing capital resources to fund its clinical development of voxelotor for the treatment of sickle cell disease, including its ongoing clinical studies, as well as preparation for the potential commercial launch of voxelotor, if approved by the U.S. Food and Drug Administration, future clinical trials of voxelotor and other product candidates that GBT may elect to pursue, including inclacumab, its other research and development activities, and for working capital and general corporate purposes.

  • Motley Foollast month

    3 Top Stocks After #ASH18

    Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.

  • Benzingalast month

    Jim Cramer Advises His Viewers On Adobe, Barnes & Noble And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said  Booz Allen Hamilton Holding Corporation (NYSE: BAH ) is not a bad stock, but he likes Accenture Plc (NYSE: ACN ) a lot more. TE Connectivity ...

  • CNBClast month

    Cramer's lightning round: Barnes & Noble's stock is trading like it could get acquired

    Jim Cramer tears through his responses to callers' questions, including one about the action in a book retailer's stock.

  • GlobeNewswirelast month

    GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2018 -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 30, 2018, the compensation.

  • Company News For Dec 4, 2018
    Zackslast month

    Company News For Dec 4, 2018

    Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT

  • Global Blood Therapeutics' Voxelotor on Faster Approval Path
    Zackslast month

    Global Blood Therapeutics' Voxelotor on Faster Approval Path

    Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics

    NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...

  • Zackslast month

    Stocks Jump 1% on 90-Day Tariff Delay

    Stocks Jump 1% on 90-Day Tariff Delay

  • Benzingalast month

    Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway

    Global Blood announced Monday that the FDA has agreed to allow filing for its late-stage sickle cell disease, or SCD, candidate Voxelotor under an accelerated approval pathway. The company said it would submit a new drug application, or NDA, for the pipeline asset under the pathway. With Global Blood proposing that voxelotor reasonably reduces strokes in SCD patients, the FDA has accepted the transcranial doppler, or TCD, flow as the primary endpoint in a post-approval confirmatory study to demonstrate stroke risk reduction.

  • Why Global Blood Therapeutics Skyrocketed Today
    Motley Foollast month

    Why Global Blood Therapeutics Skyrocketed Today

    Shares jump after the company releases upbeat clinical data and regulatory news.

  • MarketWatchlast month

    Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug

    Shares of Global Blood Therapeutics Inc. shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, works by increasing the binding of oxygen to hemoglobin, the molecule that carries oxygen in red blood cells. Global Blood thinks this would help prevent patients' red blood cells from clumping together, which would decrease the risk of stroke for those patients. Under the accelerated approval pathway, Global Blood will not need to conduct a clinical trial that proves voxelator reduces strokes until after the drug is approved, though it could be withdrawn after it hits the market if further studies show it doesn't provide a clear benefit. Shares of Global Blood have increased 11.6% in the year to date, while the S&P 500 has gained 4.3%.

  • GlobeNewswirelast month

    GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile

    Global Blood Therapeutics, Inc. (GBT) (GBT) today announced updated efficacy and safety results from Part A of its Phase 3 HOPE Study of voxelotor in patients age 12 and older with sickle cell disease (SCD). Preliminary results from 154 adolescents and adults with SCD treated with voxelotor for 24 weeks demonstrated rapid, robust and sustained improvements in hemoglobin levels and measures of hemolysis with a favorable safety and tolerability profile.

  • GlobeNewswirelast month

    GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the company will host a conference call to.